Oslo, Norway, June 1, 2022 - Nykode Therapeutics AS (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced that its
Chief Executive Officer, Michael Engsig, and Chief Innovation and Strategy
Officer, Agnete Fredriksen, will present and provide a corporate update at the
2022 Jefferies Healthcare Conference on June 8, 2022 at 8.30 p.m. CET/ 2.30 p.m.
ET and are available for 1:1 investor meetings. 

The live and archived webcast of the presentation can be accessed in the
Investors section of the Company's website
www.nykode.com/investors/financial-reports-and-presentations.  


Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer